Highly Galactosylated Anti-PD-L1 Avelumab, a Biobetter Antibody (CAT#: BioBet-GA-015ZP) Datasheet

Target
PD-L1
Isotype
Whole Human Antibody
Description
Galactosylation of the IgG Fc region has been observed to modestly enhance C1q binding and ADCC in vitro in therapeutic antibodies. The Highly Galactosylated Anti-PD-L1 Avelumab, a Biobetter Antibody contains with a high level of galactosylation, and produced by the Fc engineering platform of Creative Biolabs.
Indication
Locally advanced disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC)
Locally advanced disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC)
Metastatic Merkel Cell Carcinoma (MCC)
Metastatic disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC)
Metastatic disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC)
Classification
Therapeutic antibody; biobetter
Patent
Not Available
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Avelumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD274
Full Name
CD274 molecule
Background
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.
Alternative Names
CD274; PD-L1; PDCD1L1; B7-H; Programmed Death Ligand 1; Programmed Cell Death 1 Ligand 1; PDCD1LG1; B7H1
Gene ID
UniProt ID
Cellular Localization
Plasma membrane, Endosome
Genecards
Ensembl
OMIM
Diseases associated with CD274 include Testicular Lymphoma and Smoldering Myeloma.
Involvement in Disease
Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.
Related Pathways
1.It plays a key role in inducing and maintaining immune tolerance to oneself (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, it regulates the activation threshold of t cells and limits the effector response of t cells (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through an unknown activation receptor, it is possible to stimulate a subset of T cells to mainly produce interleukin 10 (IL10) (PubMed: 10581077). 2. Tumors use the pdcd1 mediated inhibitory pathway to weaken anti-tumor immunity and escape the destruction of the immune system, thereby promoting tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits the effector function of cytotoxic T lymphocytes (CTLs) (similar). The blockade of the pdcd1 mediated pathway leads to the reversal of the exhausted T cell phenotype and the normalization of the anti-tumor response, which provides a theoretical basis for cancer immunotherapy (through similarity).
Field of research
1.Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. 2.Glycosylation at Asn35, Asn192, Asn200, and Asn219 3.Modification sites at PhosphoSitePlus
Trade name
Bavencio
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB11945
CAS number
1537032-82-8
Antibody Isotype
Whole Human Antibody
Antibody Clone
Avelumab
Species Reactivity
Human
Description
Avelumab is a fully human monoclonal antibody that targets protein-programmed death ligand 1 (PD-L1) and was co-developed by Merck KGaA and Pfizer. Avelumab was in January 2017 the US Food and Drug Administration (FDA) approval. This drug is used in immunotherapy for a variety of diseases, including non-small cell lung cancer (NSCLC), gastric cancer, invasive skin cancer, and metastatic Merck cell cancer (MCC).
Indication
Locally advanced disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC)
Locally advanced disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC)
Metastatic Merkel Cell Carcinoma (MCC)
Metastatic disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC)
Metastatic disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC)
Synonyms
Not Available
UNII
KXG2PJ551I

Avelumab is a fully IgG1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). PD-L1 can be expressed on tumor cells and tumor-infiltrating immune cells, and can inhibit the anti-tumor immune response in the tumor microenvironment. Avelumab binds PD-L1 and prevents the interaction between PD-L1 and its receptors PD-1 and B7.1, leading to the recovery of immune responses (including anti-tumor immune responses). Avelumab has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.

Locally advanced disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC)
Locally advanced disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC)
Metastatic Merkel Cell Carcinoma (MCC)
Metastatic disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC)
Metastatic disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK